^
3d
Enrollment closed
|
triptorelin
4d
Enrollment open
|
ER positive
|
Orserdu (elacestrant) • leuprolide acetate for depot suspension
9d
Enrollment change
|
goserelin acetate
22d
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial (clinicaltrials.gov)
P2, N=75, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting
Enrollment open
|
goserelin acetate • leuprolide acetate for depot suspension
24d
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers (clinicaltrials.gov)
P2, N=21, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Enrollment closed
|
Eligard (leuprolide acetate) • Nubeqa (darolutamide) • Viadur (leuprorelin implant)
2ms
RTOG 0815: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov)
P3, N=1538, Completed, Radiation Therapy Oncology Group | Active, not recruiting --> Completed
Trial completion
|
bicalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate)
2ms
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov)
P3, N=239, Completed, Radiation Therapy Oncology Group | Active, not recruiting --> Completed | Trial completion date: Jun 2029 --> Sep 2025
Trial completion • Trial completion date
|
bicalutamide • triptorelin • goserelin acetate • flutamide • leuprolide acetate for depot suspension • orteronel (TAK 700) • Suprefact (buserelin acetate)
2ms
EVANGELINE: (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer (clinicaltrials.gov)
P2, N=87, Recruiting, Atossa Therapeutics, Inc. | N=214 --> 87 | Trial completion date: Sep 2026 --> Apr 2027 | Trial primary completion date: Feb 2026 --> Nov 2026
Enrollment change • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 negative
|
goserelin acetate
2ms
Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)" (clinicaltrials.gov)
P=N/A, N=1890, Recruiting, Takeda | N=300 --> 1890 | Trial completion date: Aug 2025 --> Apr 2026 | Trial primary completion date: Aug 2025 --> Apr 2026
Enrollment change • Trial completion date • Trial primary completion date
|
AR (Androgen receptor)
|
leuprolide acetate for depot suspension
2ms
GenSci093-301: Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects. (clinicaltrials.gov)
P3, N=211, Active, not recruiting, Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting --> Active, not recruiting
Enrollment closed
|
tamoxifen • leuprolide acetate for depot suspension
2ms
Oesophageal metastasis of prostate cancer: a case report. (PubMed, Discov Oncol)
Oesophageal metastasis of prostate cancer is extremely rare and typically indicates advanced disease with a poor prognosis. The clinical manifestations are nonspecific and often lead to misdiagnosis. A definitive diagnosis relies on histopathology and immunohistochemical markers, such as PSA and P504S. Clinicians should maintain a high index of suspicion for metastatic prostate cancer in cases of unexplained oesophageal lesions. We hope that this case will increase clinicians' awareness of metastatic oesophageal cancer.
Journal
|
AR (Androgen receptor) • CEACAM5 (CEA Cell Adhesion Molecule 5) • CA 19-9 (Cancer antigen 19-9)
|
goserelin acetate